HCA Healthcare (NYSE:HCA) Issues Quarterly Earnings Results, Beats Expectations By $0.19 EPS

HCA Healthcare (NYSE:HCA) issued its quarterly earnings data on Friday. The company reported $6.22 EPS for the quarter, topping the consensus estimate of $6.03 by $0.19, RTT News reports. HCA Healthcare had a return on equity of 520.98% and a net margin of 8.52%. During the same quarter last year, the business earned $5.90 earnings per share. HCA Healthcare updated its FY 2025 guidance to 24.050-25.850 EPS.

HCA Healthcare Stock Down 1.1 %

Shares of NYSE HCA opened at $321.77 on Friday. The company has a debt-to-equity ratio of 48.71, a quick ratio of 1.00 and a current ratio of 1.12. The stock has a 50 day moving average price of $314.50 and a 200 day moving average price of $352.84. The firm has a market capitalization of $81.50 billion, a price-to-earnings ratio of 14.45, a PEG ratio of 1.09 and a beta of 1.64. HCA Healthcare has a 52-week low of $279.93 and a 52-week high of $417.14.

Wall Street Analyst Weigh In

HCA has been the topic of a number of research reports. Morgan Stanley lowered their price target on HCA Healthcare from $406.00 to $355.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 17th. Barclays cut their price target on shares of HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. KeyCorp reduced their target price on HCA Healthcare from $420.00 to $370.00 and set an “overweight” rating on the stock in a report on Tuesday, January 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $392.00 target price on shares of HCA Healthcare in a report on Tuesday, October 1st. Finally, StockNews.com downgraded HCA Healthcare from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $385.27.

Insider Transactions at HCA Healthcare

In other HCA Healthcare news, insider Erol R. Akdamar sold 2,900 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the sale, the insider now owns 6,843 shares of the company’s stock, valued at approximately $2,415,579. The trade was a 29.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Phillip G. Billington sold 3,897 shares of the firm’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $350.00, for a total value of $1,363,950.00. Following the completion of the transaction, the senior vice president now owns 52,702 shares of the company’s stock, valued at $18,445,700. This trade represents a 6.89 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.